Shares of biotech giant Moderna (NASDAQ: MRNA) closed trading on Friday, June 26, with a strong 12% gain. As a result, the company's stock price has soared a colossal 125.51% over the past six months. This impressive surge is no coincidence, but the result of a series of fundamental changes.

Earlier, in early June, shares fell to lows around $46, but have since reversed into a confident upward trend. The key catalyst was the unanimous vote of the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) on June 18. All 9 experts supported a positive risk-benefit assessment for Moderna's experimental seasonal influenza vaccine — mFLUSIVA (mRNA-1010) for people over 50. Such rare unanimity virtually eliminated regulatory uncertainty ahead of the final decision, expected on August 5. If approved, mFLUSIVA would become the first mRNA-based seasonal influenza vaccine in the U.S.

Wall Street Remains Cautious Despite the Surge

Analyst reactions were mixed. Piper Sandler raised its price target to $77, and Jefferies to $53, maintaining a "hold" rating. However, the median market forecast remains at $43.45, significantly below current MRNA quotes. Of 16 analyst notes, the majority recommend "holding" the asset. Notably, insider transactions are dominated by sales: 75 of the latest operations were sell-offs. This suggests that even within the company, significant revenue growth from the influenza vaccine is not expected before 2027.

Not Just Vaccines: New Structure and Ambitious Plans

The market also priced in Moderna's business reorganization around three key areas: vaccines, oncology, and rare diseases. This news lifted quotes by approximately 6.3%. An even more powerful catalyst was the company's plans to invest in manufacturing capacity in Germany, including at sites that BioNTech intends to close. Market participants viewed this move as a long-term bet on increasing capacity ahead of new product launches in 2027–2028, leading to an 8–12% rise in MRNA shares over several trading sessions.

At the Science Day event on June 25, Moderna's management presented an expanded development portfolio, including programs for in vivo CAR-T and T-cell engagers for oncology and autoimmune diseases. This demonstrates that the company is striving to diversify its business beyond vaccines, which could significantly enhance its fundamental value in the long term.

Expert Opinion. Moderna's 125% surge in six months is a vivid example of how strong fundamental news and strategic reorganization can outweigh analyst skepticism. However, the current price already largely factors in future successes. The main risk is a delay in mFLUSIVA approval or weak commercial performance. Investors should closely watch the FDA's decision on August 5: it will be a key trigger for the stock's further movement.